Page 1 | Search Results | Molecular Cancer Therapeutics | American Association for Cancer Research

1-20 of 23

Sort by

Sort Order Select

Journal Articles

Abstract C151: BLU-451 is a CNS-penetrant, wild-type-sparing EGFR inhibitor with broad coverage of uncommon EGFR mutations across structure-based subsets

Xiuning Le, Yves Millet, Monique Nilsson, Aditya Dhande, Jeffrey Keats, Holly Ponichtera, Joseph Kim, Junqin He, Yasir Y. Elamin, John V. Heymach, Chiara Conti, Stephanie Lee

Mol Cancer Ther (2023) 22 (12_Supplement): C151.

https://doi.org/10.1158/1535-7163.TARG-23-C151

Published: 01 December 2023

View article titled, Abstract C151: BLU-451 is a CNS-penetrant, wild-type-sparing EGFR inhibitor with broad coverage of uncommon EGFR mutations across structure-based subsets

Journal Articles

Abstract B153: Resistance mechanisms to mobocertinib in treating NSCLC with EGFR exon 20 insertion mutations

Xiuning Le, Monique Nilsson, Sampurna Chatterjee, Zhenqiang Su, Junqin He, Hibiki Udagawa, Xiaoxing Yu, Alissa Poteete, Qian Huang, John V Heymach, Sylvie Vincent

Mol Cancer Ther (2023) 22 (12_Supplement): B153.

https://doi.org/10.1158/1535-7163.TARG-23-B153

Published: 01 December 2023

View article titled, Abstract B153: Resistance mechanisms to mobocertinib in treating NSCLC with EGFR exon 20 insertion mutations

Journal Articles

Abstract LB_B05: Mapping therapy resistant phenotypes in SCLC liquid biopsies with single-cell proteomics at a personalized level

Sayantan Bhattacharyya, Catherine A Stewart, Ashley M Victorian, Shafqat F Ehsan, Ester F Lujan, Alberto Duarte, John V Heymach, Jing Wang, Lauren A Byers, Loukia G Karacosta

Mol Cancer Ther (2023) 22 (12_Supplement): LB_B05.

https://doi.org/10.1158/1535-7163.TARG-23-LB_B05

Published: 01 December 2023

View article titled, Abstract LB_B05: Mapping therapy resistant phenotypes in SCLC liquid biopsies with single-cell proteomics at a personalized level

Journal Articles

Abstract P256: Pan-ErbB inhibition enhances activity of KRAS^G12C inhibitors in preclinical models of KRAS^G12C mutant cancers

Jacqulyne P. Robichaux, Ana Galan-Cobo, Ried T. Powell, Kelly A. Gale, Jun He, Fahao Zhang, Monique B. Nilsson, Xiang Zhang, Mary M. Sobieski, Nghi Nguyen, Stephan C. Clifford, John V. Heymach

Mol Cancer Ther (2021) 20 (12_Supplement): P256.

https://doi.org/10.1158/1535-7163.TARG-21-P256

Published: 01 December 2021

View article titled, Abstract P256: Pan-ErbB inhibition enhances activity of KRASG12C inhibitors in preclinical models of KRASG12C mutant cancers

Journal Articles

Abstract P009: A shared nearest neighbors approach for integrated, multi-platform networks and its application to the exploration of multiomics data from early-stage non-small cell lung cancers

Mol Cancer Ther (2021) 20 (12_Supplement): P009.

https://doi.org/10.1158/1535-7163.TARG-21-P009

Published: 01 December 2021

View article titled, Abstract P009: A shared nearest neighbors approach for integrated, multi-platform networks and its application to the exploration of multiomics data from early-stage non-small cell lung cancers

Journal Articles

A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers

Masanori Kawakami, Lisa Maria Mustachio, Yulong Chen, Zibo Chen, Xiuxia Liu, Cheng-Hsin Wei, Jason Roszik, Adam S. Kittai, Alexey V. Danilov, Xiaoshan Zhang, Bingliang Fang, Jing Wang, John V. Heymach, Liliya Tyutyunyk-Massey, Sarah J. Freemantle, Jonathan M. Kurie, Xi Liu, Ethan Dmitrovsky

Mol Cancer Ther (2021) 20 (3): 477–489.

https://doi.org/10.1158/1535-7163.MCT-19-0987

Published: 02 March 2021

View article titled, A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers

Includes: Supplementary data

Journal Articles

Abstract B064: The Aurora kinase A-inhibitor, alisertib, is a potential candidate for combination with immunotherapy in small cell lung cancer

Carminia M. Della Corte, Liz Lauren Ajpacaja, Robert J Cardnell, Carl M Gay, Lixia Diao, Qi Wang, Kavya Ramkumar, Allison C. Stewart, Rebecca B. Kow, Hannah E Stumpf, You-Hong Fan, Jing Wang, John V Heymach, Lauren A. Byers

Mol Cancer Ther (2019) 18 (12_Supplement): B064.

https://doi.org/10.1158/1535-7163.TARG-19-B064

Published: 01 December 2019

View article titled, Abstract B064: The Aurora kinase A-inhibitor, alisertib, is a potential candidate for combination with immunotherapy in small cell lung cancer

Journal Articles

Abstract B024: Clinical, genomic, and immune landscape of the receptor tyrosine kinase AXL in non-small cell lung cancer

Kavya Ramkumar, Carminia M. Della Corte, Lixia Diao, Robert J. Cardnell, Vali A. Papadimitrakopoulou, John V. Heymach, Jing Wang, Don L. Gibbons, Lauren A. Byers

Mol Cancer Ther (2019) 18 (12_Supplement): B024.

https://doi.org/10.1158/1535-7163.TARG-19-B024

Published: 01 December 2019

View article titled, Abstract B024: Clinical, genomic, and immune landscape of the receptor tyrosine kinase AXL in non-small cell lung cancer

Journal Articles

Abstract A077: Sustained immune response to anti-PD-1 therapy for oral premalignant lesions (OPLs) in a carcinogen-induced oral cancer mouse model

Jose Augusto Monteiro de Oliveira Novaes, Taghreed Hirz, Marlese A. Pisegna, Patrick Hwu, John V. Heymach, William N. William

Mol Cancer Ther (2018) 17 (1_Supplement): A077.

https://doi.org/10.1158/1535-7163.TARG-17-A077

Published: 01 January 2018

View article titled, Abstract A077: Sustained immune response to anti-PD-1 therapy for oral premalignant lesions (OPLs) in a carcinogen-induced oral cancer mouse model

Journal Articles

Abstract A108: DNA damage repair targeting upregulates PD-L1 level and potentiates the effect of PD-L1 blockade in small cell lung cancer

Triparna Sen, Limo Chen, B. Leticia Rodriguez, Carl M. Gay, Lerong Li, Yanli Li, Youhong Fan, Bonnie Glisson, Jing Wang, Helen Piwnica-Worms, Julien Sage, John V. Heymach, Don L. Gibbons, Lauren A. Byers

Mol Cancer Ther (2018) 17 (1_Supplement): A108.

https://doi.org/10.1158/1535-7163.TARG-17-A108

Published: 01 January 2018

View article titled, Abstract A108: DNA damage repair targeting upregulates PD-L1 level and potentiates the effect of PD-L1 blockade in small cell lung cancer

Journal Articles

Abstract B101: TrkB (NTRK2) as a potential therapeutic target in NSCLC in combination with EGFR TKIs

Mia E. Hofstad, Daniel R. Gomez, Monique B. Nilsson, Lauren A. Byers, Lixia Diao, Jing Wang, Lerong Li, Pan Tong, John V. Heymach

Mol Cancer Ther (2018) 17 (1_Supplement): B101.

https://doi.org/10.1158/1535-7163.TARG-17-B101

Published: 01 January 2018

View article titled, Abstract B101: TrkB (NTRK2) as a potential therapeutic target in NSCLC in combination with EGFR TKIs

Journal Articles

Abstract C18: Epithelial and mesenchymal phenotypic characterization and mutation detection in circulating tumor cells isolated from peripheral blood of non-small cell lung cancer patients with ApoStream® technology

Priya Balasubramanian, Vishal Gupta, David Hasegawa, Carmen Y. Lam, Ran An, Swetha Pratyusha Gunturu, Hai T. Tran, John V. Heymach, Darren W. Davis

Mol Cancer Ther (2015) 14 (12_Supplement_2): C18.

https://doi.org/10.1158/1535-7163.TARG-15-C18

Published: 01 December 2015

View article titled, Abstract C18: Epithelial and mesenchymal phenotypic characterization and mutation detection in circulating tumor cells isolated from peripheral blood of non-small cell lung cancer patients with ApoStream® technology

Journal Articles

Abstract C42: Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors

Pamela Munster, S. Gail Eckhardt, Amita Patnaik, Anthony F. Shields, Anthony W. Tolcher, S. Lindsey Davis, John V. Heymach, Lu Xu, Ann M. Kapoun, Leonardo Faoro, Jakob Dupont, Renata Ferrarotto

Mol Cancer Ther (2015) 14 (12_Supplement_2): C42.

https://doi.org/10.1158/1535-7163.TARG-15-C42

Published: 01 December 2015

View article titled, Abstract C42: Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors

Journal Articles

Abstract LB-C17: A phase I study of everolimus (mTOR inhibitor) in combination with vandetanib (multikinase inhibitor of VEGFR, EGFR, and RET) in advanced solid tumors including molecularly matched aberrations

Tina Cascone, Kenneth R. Hess, Sarina Piha-Paul, David S. Hong, Michael Roxas, Ishwaria M. Subbiah, Siquing Fu, Aung Naing, Filip Janku, Daniel Karp, Steven I. Sherman, Funda Meric-Bernstam, John V. Heymach, Vivek Subbiah

Mol Cancer Ther (2015) 14 (12_Supplement_2): LB-C17.

https://doi.org/10.1158/1535-7163.TARG-15-LB-C17

Published: 01 December 2015

View article titled, Abstract LB-C17: A phase I study of everolimus (mTOR inhibitor) in combination with vandetanib (multikinase inhibitor of VEGFR, EGFR, and RET) in advanced solid tumors including molecularly matched aberrations

Journal Articles

A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma

Tuhina Mazumdar, Lauren A. Byers, Patrick Kwok Shing Ng, Gordon B. Mills, Shaohua Peng, Lixia Diao, You-Hong Fan, Katherine Stemke-Hale, John V. Heymach, Jeffrey N. Myers, Bonnie S. Glisson, Faye M. Johnson

Mol Cancer Ther (2014) 13 (11): 2738–2750.

https://doi.org/10.1158/1535-7163.MCT-13-1090

Published: 03 November 2014

View article titled, A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma

Includes: Supplementary data

Journal Articles

Abstract B08: High-throughput synthetic lethal drug screen to identify novel radiation sensitizers for KRAS mutant non-small cell lung cancer

Steven H. Lin, Jing Zhang, Uma Giri, Clifford Stephan, Mary Sobieski, Stephen S. Yoo, John V. Heymach

Mol Cancer Ther (2013) 12 (5_Supplement): B08.

https://doi.org/10.1158/1535-7163.PMS-B08

Published: 01 May 2014

View article titled, Abstract B08: High-throughput synthetic lethal drug screen to identify novel radiation sensitizers for KRAS mutant non-small cell lung cancer

Journal Articles

Abstract C29: Characterization and identification of specific EGFR mutations in circulating tumor cells (CTCs) isolated from non-small cell lung cancer patients using an antibody independent method, ApoStream™: An update report.

Hai T. Tran, Vladislava Melnikova, Anne S. Tsao, Frank V. Fossella, Faye M. Johnson, Vali Papadimitrakoupoulou, Katherine Richardson, Marcia E. Lewis, Ben Legendre, Kenna L. Anderes, Darren W. Davis, John V. Heymach

Mol Cancer Ther (2013) 12 (11_Supplement): C29.

https://doi.org/10.1158/1535-7163.TARG-13-C29

Published: 01 November 2013

View article titled, Abstract C29: Characterization and identification of specific EGFR mutations in circulating tumor cells (CTCs) isolated from non-small cell lung cancer patients using an antibody independent method, ApoStream™: An update report.

Journal Articles

Abstract A131: Identification of candidate therapeutic targets in mesenchymal head and neck squamous cell carcinoma.

Milena P. Mak, Lixia Diao, Jing Wang, Patrick KS Ng, You-Hong Fan, Michael D. Story, William N. William, John V. Heymach, John N. Weinstein, Kevin R. Coombes, Lauren A. Byers

Mol Cancer Ther (2013) 12 (11_Supplement): A131.

https://doi.org/10.1158/1535-7163.TARG-13-A131

Published: 01 November 2013

View article titled, Abstract A131: Identification of candidate therapeutic targets in mesenchymal head and neck squamous cell carcinoma.

Journal Articles

Abstract C117: An integrated proteomic analysis of lung adenocarcinomas from The Cancer Genome Atlas (TCGA) reveals potential targets for oncogene-negative tumors.

Lixia Diao, Pan Tong, Jing Wang, You-Hong Fan, Yiling Lu, Wenbin Liu, Carmen Behrens, Ignacio I. Wistuba, John V. Heymach, John N. Weinstein, Gordon B. Mills, Lauren A. Byers

Mol Cancer Ther (2013) 12 (11_Supplement): C117.

https://doi.org/10.1158/1535-7163.TARG-13-C117

Published: 01 November 2013

View article titled, Abstract C117: An integrated proteomic analysis of lung adenocarcinomas from The Cancer Genome Atlas (TCGA) reveals potential targets for oncogene-negative tumors.

Journal Articles

Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion

Pierre Saintigny, Shaohua Peng, Li Zhang, Banibrata Sen, Ignacio I. Wistuba, Scott M. Lippman, Luc Girard, John D. Minna, John V. Heymach, Faye M. Johnson

Mol Cancer Ther (2012) 11 (9): 2021–2032.

https://doi.org/10.1158/1535-7163.MCT-12-0030

Published: 06 September 2012

View article titled, Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion

Includes: Supplementary data

NARROW

Abstract C151: BLU-451 is a CNS-penetrant, wild-type-sparing EGFR inhibitor with broad coverage of uncommon EGFR mutations across structure-based subsets

Abstract B153: Resistance mechanisms to mobocertinib in treating NSCLC with EGFR exon 20 insertion mutations

Abstract LB_B05: Mapping therapy resistant phenotypes in SCLC liquid biopsies with single-cell proteomics at a personalized level

Abstract P256: Pan-ErbB inhibition enhances activity of KRAS^G12C inhibitors in preclinical models of KRAS^G12C mutant cancers

Abstract P009: A shared nearest neighbors approach for integrated, multi-platform networks and its application to the exploration of multiomics data from early-stage non-small cell lung cancers

A Novel CDK2/9 Inhibitor CYC065 Causes Anaphase Catastrophe and Represses Proliferation, Tumorigenesis, and Metastasis in Aneuploid Cancers

Abstract B064: The Aurora kinase A-inhibitor, alisertib, is a potential candidate for combination with immunotherapy in small cell lung cancer

Abstract B024: Clinical, genomic, and immune landscape of the receptor tyrosine kinase AXL in non-small cell lung cancer

Abstract A077: Sustained immune response to anti-PD-1 therapy for oral premalignant lesions (OPLs) in a carcinogen-induced oral cancer mouse model

Abstract A108: DNA damage repair targeting upregulates PD-L1 level and potentiates the effect of PD-L1 blockade in small cell lung cancer

Abstract B101: TrkB (NTRK2) as a potential therapeutic target in NSCLC in combination with EGFR TKIs

Abstract C18: Epithelial and mesenchymal phenotypic characterization and mutation detection in circulating tumor cells isolated from peripheral blood of non-small cell lung cancer patients with ApoStream® technology

Abstract C42: Safety and preliminary efficacy results of a first-in-human phase I study of the novel cancer stem cell (CSC) targeting antibody brontictuzumab (OMP-52M51, anti-Notch1) administered intravenously to patients with certain advanced solid tumors

Abstract LB-C17: A phase I study of everolimus (mTOR inhibitor) in combination with vandetanib (multikinase inhibitor of VEGFR, EGFR, and RET) in advanced solid tumors including molecularly matched aberrations

A Comprehensive Evaluation of Biomarkers Predictive of Response to PI3K Inhibitors and of Resistance Mechanisms in Head and Neck Squamous Cell Carcinoma

Abstract B08: High-throughput synthetic lethal drug screen to identify novel radiation sensitizers for KRAS mutant non-small cell lung cancer

Abstract C29: Characterization and identification of specific EGFR mutations in circulating tumor cells (CTCs) isolated from non-small cell lung cancer patients using an antibody independent method, ApoStream™: An update report.

Abstract A131: Identification of candidate therapeutic targets in mesenchymal head and neck squamous cell carcinoma.

Abstract C117: An integrated proteomic analysis of lung adenocarcinomas from The Cancer Genome Atlas (TCGA) reveals potential targets for oncogene-negative tumors.

Global Evaluation of Eph Receptors and Ephrins in Lung Adenocarcinomas Identifies EphA4 as an Inhibitor of Cell Migration and Invasion

Email alerts

AACR Journals

Email alerts

AACR Journals

This Feature Is Available To Subscribers Only